Vancouver, BC -- (March 20, 2023) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC Markets: GBHPF / FRANKFURT: GHG) announces that the Company has now added additional exclusive global licenses for the countries of Israel, and the European Union (with extension to Morocco) from Apollon Formularies, plc. These new exclusive licenses are in addition to the previously announced exclusive licenses for the United States, Canada, and Mexico with the same exclusive license terms.
GHG is now the exclusive licensee of Apollon discoveries set forth in Apollon's PCT application for "Compositions and Methods for Treatment of Cancers" including the National Stage filings presently pending in the United States, Canada (Application No. 3,186,850), and Mexico (Application No. MX/a/2023/000946), as well as European Patent Office (Application No. 21846278.6) and Israel (ApplicationNo.300067).
GHG's exclusive licenses now also cover Apollon discoveries set forth in Apollon's PCT application for "Compositions and Methods for Treatment of Inflammation" including the National Stage filings presently pending in the U.S., Canada (Application No. 3,187,534), and Mexico (Application No. MX/a/2023/001331), as well as European Patent Office (Application No. 21849424.3) and Israel (Application No. 300240).
Stephen D. Barnhill, Jr., interim President & CEO of GHG stated "I am excited to announce the expansion of the exclusive intellectual property licenses with Apollon Formularies, plc to these new territories, and I look forward to immediately launching a sublicensing program open to legally licensed manufacturers, distributors and retail partners in these countries. It is our intention to generate upfront license fees, continuing license fees, and royalties in legal jurisdictions in these countries.”